GO
| HSI1 | 25,893.54 | +141.14 | 246.32B |
| HSCEI1 | 8,655.04 | +43.21 | 75.28B |
| Back Zoom + Zoom - Block Traded | |
|
Sino Biopharmaceutical (01177.HK) Subsidiary's Innovative Drug Kylo-11 Completes First Patient Enrollment in the US
2026-04-10 08:15:06 Sino Biopharmaceutical (01177.HK) announced that Kylo-11 "LPA siRNA", an innovative drug independently developed by its wholly owned subsidiary Hejiya Biologics, has completed enrollment of the first patient in the United States for its Phase II clinical trial (Kylo-11-II-C01) targeting atherosclerotic cardiovascular disease (ASCVD) with elevated lipoprotein(a) (Lp(a)). Previously, the China segment of the clinical trial completed enrollment of the first Chinese patient in October 2025. (ca/w) ~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |